Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics #00460

Submission Number:
00460
Commenter:
Steven Jensen
State:
Michigan
Initiative Name:
Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics
PBM's must be looked at for their opaque business practices. They extract large rebates from manufacturers and it is unclear how much of these are actually passed on to the insurance companies and how much they keep. As middlemen they are costing the health system more than they provide. The proposed merger between CVS and Aetna will most certainly result in reduced patient access as CVS will steer Aetna patients to their own pharmacies. This will reduce competition in certain markets to a large degree